We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+45.75%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$396M
AUM Growth
+$81.5M
Cap. Flow
-$53.8M
Cap. Flow %
-13.59%
Top 10 Hldgs %
82.26%
Holding
45
New
14
Increased
6
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
CASC
Cascadian Therapeutics, Inc.
CASC
+$12.6M
2
CTMX icon
CytomX Therapeutics
CTMX
+$10.5M
3
FATE icon
Fate Therapeutics
FATE
+$9.28M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$7.47M
5
TPST icon
Tempest Therapeutics
TPST
+$5.59M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$19.8M
2
ARDX icon
Ardelyx
ARDX
+$18.6M
3
KYNB
Kyntra Bio
KYNB
+$15.7M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$15M
5
EDIT icon
Editas Medicine
EDIT
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 85.89%
2 Miscellaneous 14.11%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
1
Assembly Biosciences
ASMB
$694M
$75M 18.97%
245,264
– –
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$682M
$49.6M 12.53%
3,469,185
+59,700
+2% +$816K
LKFT
3
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$47.5M 12.01%
551,041
-10,300
-2% -$742K
GILD icon
4
CALL
Gilead Sciences
GILD
$181B
$34M 8.59%
+500,000
New +$35.2M
ASND icon
5
Ascendis Pharma A/S
ASND
$16.3B
$28.7M 7.26%
1,025,700
+50,000
+5% +$1.26M
KURA icon
6
Kura Oncology
KURA
$1.13B
$23M 5.81%
2,611,906
– –
ACRS icon
7
Aclaris Therapeutics
ACRS
$885M
$20.1M 5.07%
673,100
+259,100
+63% +$7.47M
CTMX icon
8
CytomX Therapeutics
CTMX
$699M
$13.7M 3.47%
+794,969
New +$10.5M
CASC
9
DELISTED
Cascadian Therapeutics, Inc.
CASC
$12.4M 3.14%
+3,000,000
New +$12.6M
FATE icon
10
Fate Therapeutics
FATE
$291M
$11.5M 2.92%
+2,537,026
New +$9.28M
ATRA icon
11
Atara Biotherapeutics
ATRA
$92.3M
$8.94M 2.26%
17,392
+8,760
+101% +$3.63M
ATYR
12
aTyr Pharma
ATYR
$53M
$8.02M 2.03%
163,761
+93,976
+135% +$4.3M
TPST icon
13
Tempest Therapeutics
TPST
$17.5M
$6.57M 1.66%
+1,201
New +$5.59M
JNCE
14
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$5.68M 1.44%
+258,457
New +$5.48M
XNCR icon
15
Xencor
XNCR
$1.94B
$5.62M 1.42%
234,813
-140,187
-37% -$3.38M
KIN
16
DELISTED
Kindred Biosciences, Inc.
KIN
$3.84M 0.97%
544,880
-26,246
-5% -$164K
NBRV
17
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.18M 0.8%
1,059
– –
RGLS
18
DELISTED
Regulus Therapeutics
RGLS
$2.49M 0.63%
+12,583
New +$2.39M
ADVM
19
DELISTED
Adverum Biotechnologies
ADVM
$2.36M 0.6%
87,445
– –
ARAV
20
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.13M 0.54%
+16,667
New +$1.76M
VIVE
21
DELISTED
VIVEVE MED INC
VIVE
$1.58M 0.4%
+250
New +$1.22M
AGIO icon
22
Agios Pharmaceuticals
AGIO
$1.99B
$1.36M 0.34%
23,300
– –
DRNA
23
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.3M 0.33%
+382,000
New +$1.08M
KYNB
24
Kyntra Bio
KYNB
$32.5M
$1.04M 0.26%
1,680
-25,767
-94% -$15.7M
SYRS
25
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.01M 0.26%
6,360
– –
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q1 2017 Portfolio in Review

As of Q1 2017, EcoR1 Capital held 45 positions worth $396M, up 26% from $314M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

EcoR1 Capital withdrew a net $53.8M in Q1 2017, closing 12 positions and reducing 5 holdings. Its most notable exit was Alexion Pharmaceuticals, an estimated $19.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 88% a quarter earlier, followed by Miscellaneous and Industrials.

Against the trend, EcoR1 Capital opened a new position in Cascadian Therapeutics, Inc. worth $12.4M.

  • EcoR1 Capital's largest Q1 2017 buy was Cascadian Therapeutics, Inc.: 3,000,000 shares worth $12.4M.
  • EcoR1 Capital added most to Aclaris Therapeutics in Q1 2017, an estimated $7.47M increase.
  • EcoR1 Capital's biggest Q1 2017 reduction was Kyntra Bio, cutting an estimated $15.7M.
  • EcoR1 Capital fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $19.8M.
  • EcoR1 Capital's ten largest holdings make up 82% of its $396M portfolio in Q1 2017.
  • EcoR1 Capital opened 14 new positions and closed 12 in Q1 2017.
  • EcoR1 Capital's portfolio value rose 26% quarter-over-quarter to $396M.

Based on EcoR1 Capital's 13F filing for Q1 2017, filed 15 May 2017.